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Each member of the epidermal growth factor receptor (EGFR) family plays a key role
in normal development, homeostasis, and a variety of pathophysiological conditions,
most notably in cancer. According to the prevailing dogma, these four receptor tyrosine
kinases (RTKs; EGFR, ERBB2, ERBB3, and ERBB4) function exclusively through the
formation of homodimers and heterodimers within the EGFR family. These combinatorial
receptor interactions are known to generate increased interactome diversity and therefore
influence signaling output, subcellular localization and function of the heterodimer. This
molecular plasticity is also thought to play a role in the development of resistance toward
targeted cancer therapies aimed at these known oncogenes. Interestingly, many studies
now challenge this dogma and suggest that the potential for EGFR family receptors to
interact with more distantly related RTKs is much greater than currently appreciated. Here
we discuss how the promiscuity of these oncogenic receptors may lead to the formation
of many unexpected receptor pairings and the significant implications for the efficiency
of many targeted cancer therapies.
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THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY
Receptor Tyrosine Kinases (RTKs) are cell surface receptors; all possessing an extracellular ligand
binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain
(Lemmon and Schlessinger, 2010). RTKs are known to be key regulators of a diverse array of normal
cellular functions including cellular metabolism, cell proliferation, migration and differentiation
(Schlessinger, 2000). Given this central regulatory role, it is not surprising that mutation or atypical
activation of RTKs has emerged as a driver of many diseases, including a variety of different cancers
(Yarden and Sliwkowski, 2001; Stern, 2003; Lemmon and Schlessinger, 2010).
There are 58 RTKs which are subdivided into 20 subfamilies (Lemmon and Schlessinger, 2010).
One of the most intensely researched RTK families is that of the Epidermal Growth Factor Receptor
(EGFR), which consists of four members, the archetypal EGFR, and also ErbB2, ErbB3, and
ErbB4. This family of receptors plays an important role in embryonal development of the nervous,
gastrointestinal and cardiovascular system (Stern, 2003; Casalini et al., 2004). However, a large body
of research has also focused upon their role in cancer, with ectopic expression of EGFR ligands,
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mutation or overexpression of the receptors apparent in many
human cancers (Salomon et al., 1995; Rubin and Yarden, 2001;
Yarden and Sliwkowski, 2001; Stern, 2003).
As with many other RTKs, the EGFR family can be activated
by the formation of ligand-dependent dimers, both homo-dimers
and heterodimers (Lemmon and Schlessinger, 2010). Since the
discovery of oligomerization between EGFR family members
(Earp et al., 1995; Riese et al., 1995; Riese and Stern, 1998), it
has been believed that these hetero-interactions occur exclusively
within this family. However, an increasing number of studies
now suggest that the EGFR family members are capable of
more promiscuous behavior thanwas originally appreciated, with
significant implications for the signaling capacity and therapeutic
targeting of these receptors. Therefore, whilst the structure,
function and complex dimerisation mechanisms of this receptor
family have been the subject of a number of seminal review papers
(Rubin and Yarden, 2001; Yarden and Sliwkowski, 2001; Stern,
2003; Hubbard and Miller, 2007; Lemmon, 2009; Lemmon and
Schlessinger, 2010), we will focus on the key aspects of the EGFR
family necessary to appreciate the possibility and significance of
this potential promiscuity.
EGFR FAMILY DIMERISATION
EGFR family members are known to be present at the plasma
membrane as both monomers and dimers, including homo- and
hetero-dimers (Riese and Stern, 1998; Rubin and Yarden, 2001).
The extracellular region of these receptors contains four domains;
two β-helix leucine-rich repeat domains that mediate ligand
binding (Domains I and III), and two cysteine-rich domains (II
and IV) (Figure 1; Lemmon and Schlessinger, 2010). There are 11
different ligands capable of binding the EGFR family members,
albeit with differing receptor specificity (Figure 1; Yarden and
Sliwkowski, 2001; Lemmon, 2009). This ligand binding is known
to promote a conformational change within the receptor, causing
an equilibrium shift toward receptor dimerisation (Burgess et al.,
2003). The complex mechanisms associated with this process
have been the subject of intense research (Hubbard and Miller,
2007; Lemmon, 2009). Although, for the purpose of this review
it is sufficient to note the following five key aspects of EGFR
family dimerisation; (i) In the absence of ligand EGFR, ErbB3,
and ErbB4 adopt a closed conformation that prevents access to
a “dimerisation arm” within domain II (Figure 1A). (ii) Upon
ligand binding to domains I and III, a conformational change
exposes this dimerisation arm, promoting receptor dimerisation
(Figure 1B). (iii) There is no known ligand for ErbB2 and it
dimerisation arm is constitutively exposed, allowing it to freely
form heterodimers with other ligand-bound familymembers. (iv)
Following ligand-mediated receptor dimerisation, the formation
of an asymmetric kinase domain dimer promotes allosteric
activation of one kinase domain, which then performs trans- and
auto-phosphorylation of the cytoplasmic tail of both receptors
(Zhang et al., 2006; Qiu et al., 2008). (v) The kinase domain
of ErbB3 lacks enzyme activity and requires heterodimerisation
for trans-phosphorylation of its kinase domain (Jura et al.,
2009).
There are of course important caveats to this simplified
explanation of the normal functioning of EGFR family receptors.
At physiological levels of receptor expression, it is believed
that ErbB2 is unable to form homo-dimers, and exists either
solely as monomers or heterodimers with other ligand bound
family members (Yarden and Sliwkowski, 2001). However, it
is important to note that upon amplification of the ERBB2
gene, which occurs frequently in breast cancer (Slamon
et al., 1987), the highly elevated levels of ErbB2 lead to
violation of these physiological constraints and allow the
formation of both ErbB2 homo-dimers and ligand-independent
heterodimers (Worthylake et al., 1999; Yarden and Sliwkowski,
2001).
SIGNALING MECHANISMS
Once these receptors have dimerized, trans- and
auto-phosphorylation of tyrosine residues occurs within
the cytoplasmic, C-terminal tail of both receptors (Lemmon
and Schlessinger, 2010). These phospho-tyrosine residues lie
within amino acid sequence motifs that are recognized by the
Src homology 2 (SH2) and phospho-tyrosine binding (PTB)
domains of several cytoplasmic and transmembrane adaptor
proteins. Each of these receptors in isolation are potentially
capable of recruiting a diverse set of interacting proteins through
an array of different phosphosites on each receptor (Schulze
et al., 2005; Jones et al., 2006). Several well characterized
adaptor proteins are known to activate key signaling pathways
downstream of EGFR family members, including Shc (Pelicci
et al., 1992) and Grb2 (Lowenstein et al., 1992) which bind
to all family members and activate MAPK signaling through
SOS/Ras, and the PI3K pathway through GAB1 and GAB2
(Yarden and Sliwkowski, 2001; Schulze et al., 2005; Zheng et al.,
2013). While EGFR and ErbB2 indirectly activate PI3K in this
way, ErbB3, and to a lesser extent, ErbB4 have a key role in
activating PI3K signaling through the direct recruitment of
the p85 subunit of PI3K (Soltoff et al., 1994; Sepp-Lorenzino
et al., 1996; Erlich et al., 2001; Schulze et al., 2005). EGFR
and ErbB4 are unique in that they both directly bind and
activate STAT5 (Jones et al., 1999; Schulze et al., 2005), while
PLCγ can also bind to the activated EGFR (Fedi et al., 1994)
and promote PKC activation through the second messenger
diacylglycerol.
Due to the distinct adaptor binding profile of each receptor,
the formation of heterodimers within the EGFR family has long
been thought to diversify the interactome and signaling capacity
of these receptors when compared to ligand-dependent receptor
homo-dimers (Earp et al., 1995; Riese et al., 1995; Riese and Stern,
1998; Olayioye et al., 2000; Yarden and Sliwkowski, 2001). The
signals emanating from these hetero-dimers are known to be
significantly stronger than that of ligand-induced homo-dimers
(Rubin and Yarden, 2001; Yarden and Sliwkowski, 2001), and
this differential signaling output has a significant impact upon
the role of each specific dimer in cancer. Experimental studies
have shown that the oncogenicity of receptor dimers within the
EGFR family is relative to their promiscuity in binding partners
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FIGURE 1 | The EGFR receptor family. (A) A schematic showing the structure of the four EGFR family receptors (EGFR, ErbB2, ErbB3, and ErbB4), including the
four domains within the extracellular region, the intracellular tyrosine kinase domain and the ligands specific to each receptor. EGFR, ErbB3, and ErbB4 are shown in
the unliganded, “closed” conformation. (B) The conformational change associated with ligand binding, receptor dimerisation and formation of an allosteric kinase
domain dimer.
(Jones et al., 2006; Kolch and Pitt, 2010), with the ErbB2:ErbB3
heterodimer having the broadest adaptor binding profile and
also possessing the most potent transforming capacity (Alimandi
et al., 1995; Wallasch et al., 1995; Stern, 2008; Kolch and Pitt,
2010).
In addition to the recruitment of adaptor proteins for
signaling pathway activation, various components of the
endocytosis machinery also bind to these activated receptor
dimers and facilitate internalization of the entire complex (Sorkin
and Goh, 2009). This can occur through both clathrin-dependent
and independent mechanisms and can result in either signal
termination through lysosomal degradation or recycling of the
receptors to the plasma membrane (Sorkin and Goh, 2009). This
process is also tightly regulated by the distinct binding profile of
each receptor, where ErbB2, unlike EGFR, ErbB3, or ErbB4, may
have an impaired ability to undergo endocytosis due to a lack of
C-terminal internalization signals (Wang et al., 1999; Bertelsen
and Stang, 2014). Through this mechanism ErbB2 can potentiate
sustained activation and downstream signaling from other EGFR
family members through the formation of endocytosis resistant
heterodimers or alternative endosomal trafficking (Lenferink
et al., 1998; Olayioye et al., 2000; Bertelsen and Stang, 2014).
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THE EGFR FAMILY IN CANCER
As receptors to mitogenic growth factors, the EGFR family
receptors are heavily involved in the cellular processes governing
cell cycle, proliferation, and apoptosis, which makes these
receptors important in many human cancers (Stern, 2003;
Casalini et al., 2004). In general, the aberrant behavior of RTKs in
cancer is characterized by four principal mechanisms: autocrine
activation, chromosomal translocations, overexpression,
and gain of function mutations (Lemmon and Schlessinger,
2010). The behavior of EGFR family receptors in cancer is
predominantly mediated by the latter two of these mechanisms,
and overexpression and gain of function mutations of the EGFR
family have been extensively documented in the literature.
Both mutation and amplification of the prototype member,
EGFR, have been observed in a number of cancers (Normanno
et al., 2006; Lemmon and Schlessinger, 2010). Although, these
genomic alterations are particularly prevalent in triple-negative
breast cancer, with overexpression in over 60% of cases (Simon
and FitzGerald, 2016), along with over-expression in 80% of head
and neck squamous cell carcinomas (HNSCC) (Alorabi et al.,
2016), 60% of non-small-cell lung cancer (Sharma et al., 2007),
and 40% of glioblastomas (Westphal et al., 1997). Mutation
or overexpression of ErbB2 is regularly observed in lung and
gastric cancers, but is more prevalent in breast cancer, where
amplification and overexpression of the ErbB2 receptor is
strongly linked with aggressiveness of the disease and a poor
patient prognosis (Stern, 2008; Creedon et al., 2014). ErbB3
is frequently amplified or over-expressed in breast, lung, liver,
colon, gastric, and prostate cancer (Desbois-Mouthon, 2010),
and while there is no evidence to suggest that ErbB3 carries
oncogenic mutations, somatic mutations have been found to
occur in 12% of colorectal cancers (Jaiswal et al., 2013). Although,
these mutations do not necessarily confer oncogenic activity
upon ErbB3, they have been found to enhance the activation
of EGFR upon dimerisation with mutant ErbB3 (Littlefield
et al., 2014). The final member of the EGFR family, ErbB4,
is not well characterized in cancer and while existing clinical
data for the potential role of ErbB4 in breast cancer are
contradicting (Gullick, 2003) a number of activating mutations
were recently identifed in non-small cell lung cancer (Kurppa
et al., 2016).
THERAPEUTIC TARGETING
As the receptors of the EGFR family have been identified
as potent oncogenes (Stern, 2003), a number of therapeutic
agents have been developed in order to interfere and disrupt
their roles in cancer cell proliferation and survival. There are
two classes of drugs that function in this method: monoclonal
antibodies and small molecule tyrosine kinase inhibitors (TKIs).
Monoclonal antibodies act on the receptor’s extracellular domain,
interfering with the receptor through increasing internalization,
activating antibody dependent cell-mediated cytotoxicity or
disrupting receptor dimerization (Badache and Hynes, 2004).
Whereas, TKIs function by inhibiting the cytosolic tyrosine
kinase domains through either direct competition with ATP or
allosteric inhibition of ATP binding (Levitzki andMishani, 2006).
While both of these therapeutic strategies have had promising
results in both the pre-clinical setting as well as in clinical trials,
innate and acquired resistance has presented itself as a key
challenge for both types of therapies (Nguyen et al., 2009; Oxnard
et al., 2011; Stern, 2012; Arteaga and Engelman, 2014; Creedon
et al., 2014; D’Amato et al., 2015; Forde and Ettinger, 2015; Landi
and Cappuzzo, 2015; Gollamudi et al., 2016; Luque-Cabal et al.,
2016).
One prominent example is that of the EGFR targeting
monoclonal antibodies cetuximab and panitumumab, which have
improved survival for patients with metastatic colorectal cancer
harboring a wildtype KRAS (Liu et al., 2016). However, even
within this subset of patients, resistance still occurs due to
mutations that result in the activation of compensatory signaling
pathways (i.e., BRAF, PIK3CA, NRAS, and PTEN; Therkildsen
et al., 2014; Liu et al., 2016). Cetuximab is also approved for use
in HNSCC, where it is often used in combination with platinum-
based chemotherapy and radiation treatment (Sacco and Cohen,
2015; Sacco and Worden, 2016). Despite the high number of
HNSCC patients with over-expressed EGFR, there is a distinct
lack of biomarkers for response to EGFR-targeting therapies and
resistance also occurs through compensatory signaling (Sacco
and Cohen, 2015).
Non-small cell lung cancer with EGFR mutations are
particularly sensitive to EGFR TKIs erlotinib and gefitinib,
however resistance often occurs within 10–14 months of
treatment, frequently due to the acquisition of the EGFR T790M
“gatekeeper” mutation (Oxnard et al., 2011; Landi and Cappuzzo,
2015). In response to this, next-generation inhibitors are now
starting to emerge, including the pan EGFR family inhibitor
afatinib, which demonstrates a benefit both as a frontline agent
for patients with EGFR mutations and also for those that have
relapsed following erlotinib or gefitinib (Hirsh, 2015). However,
compensatory signaling through alternative RTKs such as MET
or IGF-1R (Nguyen et al., 2009), may represent another method
of resistance that might eventually circumvent a pan-EGFR
family inhibitor.
ErbB2 overexpression is a highly validated target for
monoclonal antibody therapy in breast cancer in both the
adjuvant and metastatic setting. The standard of care therapeutic
agent is trastuzumab, an antibody that targets ErbB2. However,
evenwhen patients are preselected according to ErbB2 expression
less than half respond, and most become resistant within a year
(Thery et al., 2014). Pertuzumab, an ErbB2 targeting antibody
that binds to domain II and inhibits receptor dimerization, has
added efficacy and extended survival, especially when used in
combination with trastuzumab (Kümler et al., 2014), and is now
also approved for use in the neoadjuvant setting (Gollamudi et al.,
2016). The dual-targeting TKI Lapatinib, which inhibits both
EGFR and ErbB2, is approved for use in ErbB2 positive breast
cancer upon relapse following treatment standard chemotherapy
and trastuzumab (Nolting et al., 2014). Although, a number of
different mechanisms of both acquired and innate resistance to
lapatinib have been identified, including compensatory signaling,
mutation of ErbB2 and reactivation of the estrogen receptor
pathway (D’Amato et al., 2015).
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As ErbB3 lacks kinase activity, it cannot be targeted with a
small molecule inhibitor. While there are currently no clinically
approved monoclonal antibodies that target ErbB3, a number
of different strategies are currently being tested (Gaborit et al.,
2016). However, in keeping with the established oncogenecity
of the ErbB2:ErbB3 heterodimer, recent data from preclinical
models also suggests that the simultaneous targeting of ErbB2
and ErbB3 by a bispecific antibody (MM-111) has promising
activity as single agent and in combination with trastuzumab
(McDonagh et al., 2012). In line with the ability of ErbB3 to
form heterodimers with receptors from outside the EGFR family,
a bispecific antibody toward the ErbB3:IGF-1R heterodimer has
also been developed (Fitzgerald et al., 2014).
Attempts to address this common theme of resistance toward
EGFR-family targeted therapies has been met with only partial
success (Creedon et al., 2014; D’Amato et al., 2015), indicating
that our understanding of acquired resistance in this context is
not sufficiently developed. Acquired resistance to EGFR family
targeted therapies has been variously attributed to a change in
receptor expression or structure, the development of alternative
means of activating survival and proliferation pathways governed
by the EGFR family, and by a shift in dimerization profile of
these receptors (Sergina et al., 2007; Stern, 2012; Arteaga and
Engelman, 2014; Creedon et al., 2014; Luque-Cabal et al., 2016).
While a shift in dimerization profile is commonly accepted as
a mechanism conferring resistance to EGFR family targeted
therapies, this avenue of thought has not been completely
explored. Historically, it has been accepted that EGFR family
receptors only form dimers with other members of the family.
However, studies have now emerged indicating that due to the
plasticity of these receptors, the pool of potential heterodimers
is much larger than previously thought. Therefore, a thorough
understanding of these potential interaction partners and their
effect on EGFR family signaling pathways is needed to provide
specific cancer therapies that overcome the challenge of acquired
resistance.
ALTERNATIVE HETERO-INTERACTIONS
FOR EGFR FAMILY MEMBERS
In the two decades since the discovery of heterodimerisation
between EGFR family members (Earp et al., 1995; Riese et al.,
1995; Riese and Stern, 1998), the dogma in this field has kept these
interactions strictly within the family. Whilst this restricted view
may indeed hold at physiological levels of receptor expression,
the amplification and up-regulation of each of these receptors in
cancerous tissue suggest that within patho-physiological settings
the capability of these receptors to form heterodimers with
each other, and indeed other more distantly related RTKs,
is greatly increased. This is particularly likely in the case of
breast cancer cells where ErbB2 is amplified and over-expressed,
leading to the formation of ErbB2-containing heterodimers in a
ligand-independent manner (Worthylake et al., 1999; Yarden and
Sliwkowski, 2001).
This hypothesis of EGFR family promiscuity is supported
by many experimental observations of RTKs from outside of
the EGFR family interacting with either EGFR, ErbB2, or
ErbB3 (Table 1). Although, no alternative RTK interactions with
ErbB4 could be found in the literature. Of these alternative
RTKs, MET, IGF-1R and AXL were all observed to interact
with EGFR, ErbB2, and ErbB3. Whilst RET and FGFR2 also
interacted with both EGFR and ErbB3. Interestingly, in these
studies MET was also observed interacting with RET (Tanizaki
et al., 2011; Meyer et al., 2013), AXL (Meyer et al., 2013),
and FGFR2 (Chang et al., 2015), while AXL was observed
interacting with PDGFRb (Meyer et al., 2013), suggesting that the
potential combinatorial hetero-interactions between RTKs may
be even more complex than we are currently proposing. With the
exception of two studies, all of these observed hetero-interactions
occurred within cancer cell lines that were either amplified or
over-expressing one of the interacting receptors. These findings
suggest that while specific heterodimers, such as EGFR:IFG-1R,
may have important physiological roles (Ahmad et al., 2004),
the over-expression or amplification of RTKs within this patho-
physiological setting may be driving the formation of complex
receptor interactions that would not otherwise occur in normal
biology.
With only one exception, co-immunoprecipitation was the
only experimental technique utilized to observe all of these
receptor interactions (Table 1). Additionally, a number of these
studies did not utilize sufficient non-specific binding controls or
include satisfactory data to demonstrate enrichment of the target
RTK or confirm equal loading. This lack of controls is especially
evident where the interpretation of immunoprecipitation results
has been confounded by the presence of antibody based targeted
therapies. This particular problem was previously observed for
the ErbB2:IGF-1R heterodimer, where the dimer was strongly
detected following IGF-1R immunoprecipitation in Trastuzumab
resistant SKBR3 and BT474 cells that were cultured continuously
in the presence of Trastuzumab (Nahta et al., 2005; Huang
et al., 2010). Due to a lack of sufficient non-specific binding
controls, this strong interaction was later confirmed to be
mediated instead by direct immunoprecipitation of ErbB2 by
Trastuzumab (Browne et al., 2011), although this heterodimer
was still detected in the absence of Trastuzumab, albeit at a
somewhat lower level (Browne et al., 2011). Despite this, the
number of adequately controlled experiments identifying these
non-canonical interactions suggests that it is now important that
more advanced techniques are applied to the investigation of
these potential heterodimers.
STRUCTURAL CONSIDERATIONS
The structural nature of these interactions also needs to be
established, as co-immunoprecipitation data does not confirm
a direct, physical interaction between these two receptors, and
could also be interpreted that they are contained merely within
the same multi-molecular complex. The interaction of EGFR
family receptors with a wider array of RTKs is also potentially
complicated by the differing dimerisation mechanisms present
within the different families of RTKs (Lemmon and Schlessinger,
2010). Dimerisation within the EGFR family occurs entirely
through contacts between the two receptor molecules (Garrett
et al., 2002; Ogiso et al., 2002), whereas NTRK1 dimerisation
is entirely ligand-mediated (Wehrman et al., 2007) and FGFR
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TABLE 1 | Alternative receptor tyrosine kinases observed to form heterodimers with members of the EGFR family.
EGFR
family
member
Interacting
RTK
Detection
method
Sufficient
controls
Sufficient
loading
Functional outcome of heterodimer formation Tissue References
EGFR
FGFR2 co-IP No No Resistance to FGFR2 inhibitor (AZD4547), possibly
through ERK activation.
SNU16 and KATOIII
gastric cancer cell lines
Chang et al., 2015
AXL Cross-linking
co-IP
Yes Yes Ligand induced, EGFR mediated phosphorylation of
AXL. Increased Akt signaling, cell motility and
resistance to erlotinib.
MDA-MB-231 and
MCF-7 breast cancer
cell lines
Meyer et al., 2013
MS Yes Yes HGF-induced EGFR inhibition, resulting in increased
interaction and activation of AXL.
SCC9 HNSCC cell line Gusenbauer et al.,
2013
co-IP No Yes
EPHA2 MS Yes Yes HGF-induced EGFR inhibition, resulting in increased
interaction and activation of EphA2.
SCC9 HNSCC cell line Gusenbauer et al.,
2013
co-IP No Yes
IGF1R co-IP Yes No Heterodimer induced by both IGF-1 and EGF.
Increased IGF-1 induced ERK activation.
Normal mammary
epithelial cells
Ahmad et al., 2004
MET MS Yes Yes HGF-induced EGFR inhibition through ERK
signaling. Resistance to gefitinib.
SCC9 HNSCC cell line Gusenbauer et al.,
2013
co-IP Yes Yes Transactivation of EGFR by MET in MET amplified
cells. Depletion of EGFR inhibited ERK and AKT
activation, promoting apoptosis.
EBC-1 and H1993
non-small lung cancer
cell lines
Tanizaki et al.,
2011
co-IP No Yes EGF or TGFα induced unidirectional transactivation
of MET by EGFR.
HepG2, AKN-1, and
HuH6 human
hepatoma cell lines.
A431 human
epidermoid carcinoma
cell line
Jo et al., 2000
co-IP Yes Yes c-Src dependent transactivation of MET by EGFR,
in the absence of HGF. Promotes cell proliferation
and resistance to EGFR inhibitors.
SUM229 breast cancer
cell line
Mueller et al., 2010
PDGFR co-IP No Yes Heterodimers detected, no function attributed. Malignant peripheral
nerve sheath tumor
samples
Perrone et al.,
2009
Cross-linking
co-IP
Yes Yes c-Src dependent transactivation of EGFR by
PDGFRβ, following PDGF stimulation. Promotes
ERK activation.
Rat aortic vascular
smooth muscle cells
Saito et al., 2001
co-IP Yes No Ligand independent transactivation of PDGFRβ by
EGFR observed in EGFR over-expressing cells.
COS-7 and Hs27 cell
lines
Habib et al., 1998
RET co-IP Yes Yes EGF dependent transactivation of RET by EGFR.
Promotion of cell proliferation.
PCCL3 papillary thyroid
carcinoma cell line
Croyle et al., 2008
ErbB2
MET co-IP Yes Yes Transactivation of ErbB2 by MET in MET amplified
cells. Depletion of ErbB2 inhibited ERK and AKT
activation, promoting apoptosis, and STAT3
activation, inhibiting migration.
EBC-1 and H1993
non-small lung cancer
cell lines
Tanizaki et al.,
2011
AXL Cross-linking
co-IP
Yes Yes Inferred resistance to lapatinib. MDA-MB-231 and
MCF-7 breast cancer
cell lines
Meyer et al., 2013
NTRK1 co-IP Yes Yes NGF induced transactivation of ErbB2 by NTRK1,
promoting ERK activation and proliferation.
SKBR3 breast cancer
cell line
Tagliabue et al.,
2000
IGF-1R co-IP Yes Yes Transactivation of ErbB2 by IGF-1R. Interaction
induced by heregulin and IGF-1.
C4HD and MCF-7
breast cancer cell lines
Balañá et al., 2001
co-IP No Yes Transactivation of ErbB2 by IGF-1R, leading to
trastuzumab resistance.
SKBR3 breast cancer
cell line
Nahta et al., 2005
(Continued)
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TABLE 1 | Continued
EGFR
family
member
Interacting
RTK
Detection
method
Sufficient
controls
Sufficient
loading
Functional outcome of heterodimer formation Tissue References
co-IP No Yes Hetero-dimer present in trastuzumab resistant cells.
Proposed hetero-trimer with ErbB3.
SKBR3 and BT474
breast cancer cell line
Huang et al., 2010
co-IP Yes Yes Dual targeting of ErbB2:IGF-1R heterodimer
increases sensitivity to trastuzumab.
SKBR3 and BT474
breast cancer cell line
Browne et al.,
2011
ErbB3
RET PLA, co-IP
(transfected
ErbB3)
Yes Yes May promote vandetanib resistance. 1765–92 Myxoid cell
line
Safavi et al., 2016
AXL Cross-linking
co-IP
Yes Yes Inferred resistance to ErbB3 targeted therapy. MDA-MB-231 and
MCF-7 breast cancer
cell lines
Meyer et al., 2013
MET co-IP Yes Yes Transactivation of ErbB3 by MET, in MET amplified
cells. Depletion of ErbB3 inhibited ERK and AKT
activation, promoting apoptosis.
EBC-1 and H1993
non-small lung cancer
cell lines
Tanizaki et al.,
2011
co-IP No Yes Transactivation of ErbB3 by MET in MET amplified
cells. Promotes PI3K pathway activation and
resistance to gefitinib
HCC827 NSCLC cell
line
Engelman et al.,
2007
IGF-1R co-IP No Yes Promotes trastuzumab resistance, proposed
hetero-trimer with ErbB2.
SKBR3 and BT474
breast cancer cell line
Huang et al., 2010
FGFR2 co-IP No No Resistance to FGFR2 inhibitor (AZD4547), possibly
through ERK activation.
SNU16 and KATOIII
gastric cancer cell lines
Chang et al., 2015
family dimers form through a combination of both ligand
and receptor-mediated contacts, with the addition of heparin-
mediated stabilization (Schlessinger et al., 2000). However,
despite their mechanistic differences, both NTRK1 and FGFR2
have been observed interacting with EGFR family receptors
(Table 1). It is therefore tempting to speculate that the formation
of heterodimers between RTKs with vastly different mechanisms
of ligand binding and extracellular domain interaction, could
instead be mediated through interactions at the transmembrane
or intracellular region. In support of this, the transmembrane
alpha helices of EGFR family receptors can also mediate both
ligand-dependent and -independent interactions (Burke and
Stern, 1998; Mendrola et al., 2002; Gerber et al., 2004). GXXXG
motifs within the transmembrane regions are considered to be a
general dimerisation motif for transmembrane helices (Lemmon
et al., 1994), which promote hetero-interactions within the EGFR
family (Escher et al., 2009) but are notably present within a
number of different RTKs (Mendrola et al., 2002). These GXXXG
motifs are thought to maintain the correct alignment of kinase
domains within inactive, pre-formed receptor dimers and also
facilitate formation of the activated assymetrical kinase dimer
upon ligand binding (Kovacs et al., 2015). However, these motifs
may also facilitate a wider range of receptor interactions (Sawma
et al., 2014). From the studies identified in Table 1, it is also
notable that the EGFR-RET association did not require the
extracellular domain of RET (Croyle et al., 2008), confirming that
these interactions can occur solely through transmembrane or
cytosolic contacts.
The role of ligand binding also needs to be investigated
within this expanded paradigm. From the studies that observed
non-canonical RTK interactions (Table 1), one study using
normal mammary epithelial cells noticed an increase in
EGFR:IGF-1R dimerisation following either EGF or IGF-1
treatment (Ahmad et al., 2004). In contrast, many other
studies using cancer cell lines noted that various heterodimers
were already present under basal conditions and that ligand
stimulation of one receptor increased trans-phosphorylation
of its interacting partner (Habib et al., 1998; Jo et al., 2000;
Tagliabue et al., 2000; Saito et al., 2001; Croyle et al., 2008; Meyer
et al., 2013). One of these studies also noted that EGFR:MET
heterodimers were detectable in a ligand-independent manner
in hepatoma cells, but absent in normal hepatocytes, even
in the presence of ligand (Jo et al., 2000). However, another
detected EGFR:PDGFRβ heterodimers in rat aortic vascular
smooth muscle cells in the absence of ligand (Saito et al., 2001).
These potentially conflicting findings may be reconciled when
it is considered that Src activity was often required for the
formation of these heterodimers (Saito et al., 2001; Mueller et al.,
2010), suggesting that while elevated receptor expression may
play a significant role in the formation of ligand-independent
hetero-dimers, the signaling state of the cell is also an important
consideration. Nonetheless, the bulk of these studies suggest that
cancerous cells may present a uniquely rich environment of non-
physiological receptor interactions that greatly alter the signaling
landscape of these cells, but may also render them amenable to
therapeutic targeting.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 August 2016 | Volume 4 | Article 88
Kennedy et al. Alternative Heterodimers with the EGFR Family
THERAPEUTIC IMPLICATIONS
One common functional outcome associated with the formation
of these alternative hetero-dimers is the emergence of resistance
to targeted therapy toward either interacting receptor (Table 1).
A potential mechanism for this therapeutic resistance is the
ability of EGFR family members to co-opt signaling capacity
through these alternative receptor interactions. Due to an
increase in interactome diversity, the signaling capacity of
EGFR family heterodimers is significantly stronger than that of
homodimers (Rubin and Yarden, 2001), and the oncogenicity of
these receptor dimers is also relative to their interactome diversity
(Jones et al., 2006). Through the formation of an expanded
repertoire of heterodimers with more distantly related RTKs,
there is an even greater potential for increased interactome
diversity for these alternative heterodimers. There is some
emerging recognition of this potential resistance mechanism
in the development of bivalent antibody therapy targeting the
ErbB3:IGF-1R heterodimer (Fitzgerald et al., 2014). In this
study, the concurrent inhibition of both IGF-1R and ErbB3
prevented the emergence of compensatory PI3K/mTOR signaling
associated with IGF-1R TKI treatment. Many of the studies in
Table 1 also implicated signaling pathways activated by aberrant
heterodimers in the resistance to targeted therapy. This most
commonly involved ERK (Tagliabue et al., 2000; Saito et al.,
2001; Ahmad et al., 2004; Tanizaki et al., 2011; Chang et al.,
2015) or Akt (Tanizaki et al., 2011) activation, and suggests
that rationalized therapeutic strategies capable of specifically
targeting these heterodimers may prevent resistance occurring
via downstream pathway compensation.
The role of targeted therapeutics in the inhibition/formation
of these alternative heterodimers also needs to be addressed.
Interestingly, previous observations have noted an increased
trans-phosphorylation of EphA2 by ErbB2 following treatment
with Trastuzumab (Zhuang et al., 2010). Although the potential
for heterodimerisation between these two RTKs was not
addressed in this study, a number of other studies have
demonstrated the ability of alternative RTKs to mediate
resistance to ErbB2 monoclonal antibodies (Table 1). Given that
these monoclonal antibodies target the extracellular regions of
these receptors, and intracellular/transmembrane regions may be
involved in promoting heterodimerisation with alternative RTKs,
the possibility that these artificial ligands may promote a shift
in the dimerisation profile of their target receptor should be
thoroughly addressed.
The formation of alternative heterodimers may also
impact the efficacy of TKIs targeting EGFR or ErbB2. These
small molecule inhibitors have been shown to increase the
interaction between heterodimers within the EGFR family
(Macdonald-Obermann et al., 2013) and also lead to sub-cellular
redistribution and compensation by alternative receptors,
including ErbB3 (Sergina et al., 2007). From a mechanistic
viewpoint, the ability of these TKIs to inhibit the kinase activity
of EGFR and/or ErbB2 may not prevent the kinase domain
of that receptor acting as an allosteric activator for the kinase
domain of an alternative interaction partner, and thereby
undergoing trans-phosphorylation despite the presence of a
kinase inhibitor. This was noted in studies of MET amplified
lung cancer cells, which demonstrated that the formation of
EGFR:MET (Mueller et al., 2010; Tanizaki et al., 2011) and
ErbB2:MET (Tanizaki et al., 2011) heterodimers rendered the
EGFR family member resistant to dephosphorylation in the
presence of their respective TKI (Tanizaki et al., 2011). A similar
observation was also made for the EGFR:PDGFRβ (Saito et al.,
2001) and ErbB2:NTRK1 (Tagliabue et al., 2000) heterodimers,
in which EGFR family member auto-phosphorylation occurred
following ligand activation of the interacting receptor, even in the
presence of their respective kinase domain inhibitor. A similar
mechanismwas also observed for mutationally inactivated kinase
domain (Deb et al., 2001), where an EGF-bound mutant EGFR
could still induce MAPK and PI3K pathway activation through
ErbB2. Taken together, all of these observations suggest that the
formation of alternative heterodimers may still serve to increase
the interactome diversity and signaling capacity of EGFR family
containing heterodimers, even in the presence of TKIs.
FUTURE PERSPECTIVES
With the exception of two studies (Gusenbauer et al., 2013;
Meyer et al., 2013), there has been little effort to systematically
investigate the wide array of potential heterodimers that may
formwith EGFR family members. Given the wide-ranging nature
of these oncogenic receptors, their frequent therapeutic targeting
and proclivity for adaptation and therapeutic resistance, focus
should be placed upon their ability to distribute their oncogenic
signaling capacity across an array of potential RTK interacting
partners. The increased interactome diversity and signaling
potential associated with the formation of these alternative
heterodimers is also an important avenue of research. In this
regard, we recently developed a novel affinity purification
technique that facilitates the specific isolation and proteomic
characterization of receptor dimers, and indeed any other protein
dimer of interest (Croucher et al., 2016). We applied this
technique to investigate the interactome of ErbB2 in the form
of a homodimer or a heterodimer with either EGFR or ErbB3.
This analysis revealed dimer-specific interaction patterns for
key adaptor proteins and also identified a number of novel
interacting partners that underlie the signaling capacity of
each receptor dimer. In the future, the application of such
techniques to alternative heterodimers will facilitate the detailed
investigation of their interactomes and signaling capacity,
potentially identifying new therapeutic strategies to target these
heterodimers.
As it becomes increasingly apparent that monotherapy is
an inefficient strategy for therapeutically targeting signaling
molecules in cancer cells, more elegant approaches will need to
be developed that encapsulate the plasticity and adaptability of
their extant network structure. The promiscuous EGFR receptor
family members and their many interaction partners sit at the
top of many of these network structures, and their surface
availability will continue to make them attractive therapeutic
targets. Hopefully, as we begin to unravel their under-appreciated
mechanisms for generating therapeutic resistance we can move
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toward effective and durable strategies to target these potent
oncogenes.
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